2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Young Adult
PAPER

3284 Outcomes of third-line therapy in adults with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Eitan Kugler, MD PhD, Rebecca Garris2, Wei Ying Jen, BM BCh, FRCPath3, Sherry Pierce, BSN, RN4, Nitin Jain, MD5, Nicholas Short, MD6, Issa F. Khouri, MD7, Sanam Loghavi, MD8, Fadi G. Haddad, MD9, Farhad Ravandi, MD10, Hagop Kantarjian, MD11, Elias Jabbour, MD12
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background:
The incorporation of CD19- and CD22-directed therapies, including blinatumomab and inotuzumab ozogamicin, has substantially improved outcomes for adults with B-cell acute lymphoblastic leukemia (B-ALL) in both frontline and first salvage settings. However, outcomes after a second relapse requiring third-line therapy remain poorly defined. Contemporary benchmarks are needed to inform patient counseling and provide historical comparators for emerging therapies, including novel bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell approaches.

Methods:
We retrospectively analyzed 256 adults with Philadelphia chromosome-negative B-cell ALL treated with third-line therapy at MD Anderson Cancer Center between 2000 and 2024. Third-line therapy was defined as treatment administered for active leukemia following failure of frontline and second-line therapy. Outcomes evaluated included complete remission (CR), induction mortality, and overall survival (OS).

Results:
The median age was 36 years (range, 18-86 years), and 22% of patients were aged ≥60 years. The overall CR rate was 52% and improved over time, from 41% during 2000-2009 to 54% during 2010-2016 and 56% during 2017-2024. CR rates varied by treatment modality and were highest with CAR T-cell therapy or allogeneic stem cell transplantation-based approaches (79%), followed by single-agent blinatumomab or inotuzumab (70%), chemotherapy combined with blinatumomab and/or inotuzumab (61%), chemotherapy alone (45%), and other therapies (29%).

Induction mortality was 9% overall and remained stable across treatment eras (8%-10%). With a median follow-up of 51 months, median OS was 5 months, and the overall 3-year OS rate was 13%. Survival improved over time, with the 3-year OS rate increasing from 8% before 2017 to 27% from 2017 onward. Treatment modality and treatment era were strongly correlated, with newer combination approaches used predominantly in more recent years.

Conclusions:
Outcomes of adults with relapsed/refractory Philadelphia chromosome B-cell ALL receiving third-line therapy have improved significantly in the modern era. The introduction of blinatumomab-, inotuzumab-, and cellular therapy-based strategies has increased remission rates and translated into meaningful long-term survival gains, with 3-year OS improving more than threefold since 2017. These results provide an important contemporary benchmark for evaluating emerging therapies in the third-line setting.

 

Eitan Kugler, MD PhD: No relevant conflicts of interest to declare.